MedTrace Logo

Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

NCT05072600 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2022-01-10

No results posted yet for this study

Summary

This is a Phase II, single-arm, study of pembrolizumab as maintenance therapy in muscle-invasive bladder cancer (MIBC) participants who have received maximum TURBT and tri-modality treatment (TMT) and achieved CR. All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.

Conditions

  • Bladder Cancer
  • Bladder Neoplasms
  • Bladder Tumors
  • Urinary Bladder Cancer
  • Neoplasms, Bladder

Interventions

DRUG

Pembrolizumab

pembrolizumab 200 mg Q3W

Sponsors & Collaborators

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Zhi-Song He, MD · Peking University First Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-07
Primary Completion
2024-12-07
Completion
2029-11-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05072600 on ClinicalTrials.gov